Depot versus daily administration of gonadotrophin-releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles

Albuquerque, L.E.T.; Tso, L.O.; Saconato, Humberto; Albuquerque, M.C.R.M.; Macedo, Cristiane R

doi:10.1002/14651858.cd002808.pub3

Cited by 55 publications

(33 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The most effective form of agonist protocol remains controversial. In 2013, a meta‐analysis study showed that it was not clear which one was the better protocol for pituitary desensitization in IVF cycles . This retrospective analysis aimed to compare the use of the short‐ and long‐acting long protocols with IVF cycles to study the effectiveness and safety of the two protocols.…”

Section: Introductionmentioning

confidence: 99%

“…Reducing the level of LH could improve the oocyte development by increasing the estrogen/androgen ratio 4 ; moreover, it would improve the endometrial receptivity and wide implantation window. [5][6][7][8] A Cochrane review showed that the long protocol was associated with the best clinical pregnancy rate among the variety of controlled ovarian hyperstimulation (COH) protocols, 9 and was recommended by the National Institute for Health and Care Excellence. The long protocol has two forms: the long-acting and short-acting long protocol.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comparing the long‐acting and short‐acting forms of gonadotropin‐releasing hormone agonists in the long protocol of IVF/ICSI Cycles: A retrospective study

Duan

Bao

Teng

et al. 2017

J of Obstet and Gynaecol

View full text Add to dashboard Cite

Aim: This study aimed to compare the efficacy of long-and short-acting gonadotropin-releasing hormone agonist on clinical outcomes of in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) long protocol cycles. Methods: In this retrospective study, 478 patients were enrolled from October 2012 to November 2014. The pituitary downregulation result, serum hormone levels, gonadotropin (Gn) dose during controlled ovarian hyperstimulation, and outcome of IVF/ICSI-embryo transfer were compared between the two groups. Results: Compared with the long-acting group, in the short-acting group the duration of downregulation and stimulation was significantly shorter; the total Gn doses, cost of an IVF cycle, rate of ovarian hyperstimulation syndrome, superior-quality embryo rate, and implantation rate were significantly lower; and the serum luteinizing hormone concentrations on the day of Gn and human chorionic gonadotropin administration were significantly higher. The serum estradiol level on the day of human chorionic gonadotropin was higher in the long-acting group. However, no significant differences were noted in other parameters. Conclusion: The long-acting group was associated with greater amounts of Gn and a longer duration of use for ovarian stimulation. This increased the cost per IVF cycle and may have had a detrimental effect on the pregnancy outcome because of a subsequent increase in the rate of ovarian hyperstimulation syndrome and decrease in the superior-quality embryo rate and implantation rate.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Comparing the long‐acting and short‐acting forms of gonadotropin‐releasing hormone agonists in the long protocol of IVF/ICSI Cycles: A retrospective study

Duan

Bao

Teng

et al. 2017

J of Obstet and Gynaecol

View full text Add to dashboard Cite

show abstract

“…Systematic reviews (e.g. from the Cochrane collaboration) are regularly issued in order to compare different protocols but often fail to demonstrate the purported superiority of the new approaches (3,4,5,6). On the other hand, new protocols of infertility treatment and ART are greatly needed, especially considering the constantly increasing age of women in couples undergoing ART (7), a factor which decreases the efficacy of the treatment by affecting both pregnancy and abortion rate.…”

Section: Introductionmentioning

confidence: 99%

MECHANISMS IN ENDOCRINOLOGY: Genetics of FSH action: a 2014-and-beyond view

Simoni

Casarini

2014

European Journal of Endocrinology

123

View full text Add to dashboard Cite

Objective: To assess the pharmacogenetic potential of FSH for infertility treatment. Design: Review of the literature and genomic databases. Methods: Single-nucleotide polymorphism (SNP) assessed: rs6166 (c.2039AOG, p.N680S), rs6165 (c.919AOG, p.T307A), rs1394205 (c.K29GOA) in FSHR, and rs10835638 (c.K211GOT) in FSHB. Literature search via PubMed. Blast analysis of genomic information available in the NCBI nucleotide database. Comparison of allele frequency and haplotype distribution using the http://spsmart.cesga.estool. Results: All these SNPs appear first in Homo, result in reduced FSH action, and are present with variable frequencies and combinations worldwide. Stringent clinical studies demonstrate that the FSHR genotype influences serum FSH levels and gonadal response in both sexes. Serum FSH levels depend on the K211GOT SNP, influencing transcriptional activity of the FSHB promoter. Genotypes reducing FSH action are overrepresented in infertile subjects. Conclusions: Although the clinical relevance of the FSHR polymorphisms alone is limited, the combination of FSHR and FSHB genotypes has a much stronger impact than either one alone in both sexes. About 20% of people are carriers of the alleles associated with lower serum FSH levels/reduced FSHR expression or activity, possibly less favorable for reproduction. Prospective studies need to investigate whether stratification of infertile patients according to their FSHR-FSHB genotypes improves clinical efficacy of FSH treatment compared with the current, naïve approach. A relative enrichment of less favorable FSHR-FSHB genotypes may be related to changes in human reproductive strategies and be a marker of some health-related advantage at the cost of reduced fertility.

show abstract

“…Efforts have been made to optimize protocols for controlled ovarian stimulation to provide adequate numbers of good-quality oocytes, which is the cornerstone of assisted reproductive techniques. The Cochrane Database of Systematic Reviews is regularly published to compare different protocols but often fail to demonstrate the purported superiority of the new approaches [35][36][37][38]. However, to be able to successfully achieve this, an ORT needs to have a high specificity and predictive value, as well as reproducibility [34].…”

Section: Discussionmentioning

confidence: 99%

FSHR gene polymorphisms affect the ovarian response to rFSH stimulation in Egyptian patients undergoing ARTs

El-Garf¹,

Salem²,

Elnouri

et al. 2014

Medical Research Journal

View full text Add to dashboard Cite

Objective The aim of the study was to assess the potential of follicle-stimulating hormone receptor (FSHR) gene polymorphism for predicting ovarian response to FSH stimulation.Methods We retrospectively analyzed clinical data of 150 infertile women younger than 40 years who were attending the National Research Center infertility clinic, Egypt. These women were divided into two groups: group I patients (75 patients) were considered as poor ovarian responders according to the 'Bologna criteria' and group II patients (75 patients) were considered as good responders. Analysis of FSHR gene polymorphism at position 680 was carried out after the women were genotyped.Results Among Egyptian women, the frequency of the Asn/Asn genotype was significantly more prevalent in the poor responder group (65.3%) compared with the good responder group (24.0%) (P < 0.05); the Ser/Asn genotype was seen in 34.7% of poor responders compared with 64% of good responders and the Ser/Ser phenotype was seen only in good responders (12%).

show abstract

Depot versus daily administration of gonadotrophin-releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles

Abstract: Depot versus daily administration of gonadotrophin-releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles.

Cited by 55 publications

References 47 publications

Comparing the long‐acting and short‐acting forms of gonadotropin‐releasing hormone agonists in the long protocol of IVF/ICSI Cycles: A retrospective study

Comparing the long‐acting and short‐acting forms of gonadotropin‐releasing hormone agonists in the long protocol of IVF/ICSI Cycles: A retrospective study

MECHANISMS IN ENDOCRINOLOGY: Genetics of FSH action: a 2014-and-beyond view

FSHR gene polymorphisms affect the ovarian response to rFSH stimulation in Egyptian patients undergoing ARTs

Contact Info

Product

Resources

About